{"filing":{"accession_number":"0001437749-26-031005","cik":"0001659617","ticker":"MBRX","company_name":"Moleculin Biotech, Inc.","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"mbrx20260922_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926031005/mbrx20260922_8k.htm"},"events":[{"id":34500,"run_id":31745,"accession_number":"0001437749-26-031005","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Moleculin announced the grant of Mexican Patent No. 436849 protecting its proprietary lung-targeted liposomal Annamycin technology through 2040, strengthening the company's global patent estate and providing long-term commercial protection for its lead clinical-stage asset.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38241,"accession_number":"0001437749-26-031005","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the grant of Mexican Patent No. 436849 protecting Moleculin's proprietary lung-targeted liposomal Annamycin technology through 2040. This is a material intellectual property milestone that strengthens the company's global patent estate and supports long-term commercial protection of its lead clinical-stage asset. While not fitting a specific named event type, this is clearly an operational/strategic business event—a regulatory/IP milestone—that would affect a reasonable investor's assessment of the company's competitive position and asset value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:26:52.216184+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":34501,"run_id":31745,"accession_number":"0001437749-26-031005","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Moleculin completed two dilutive equity issuances: (1) an ATM offering of 888,400 shares for $0.48 million in September 2026, and (2) a public offering of Series I Warrants to purchase 37,130,001 shares on August 3, 2026, with anti-dilution provisions that reduced the warrant exercise price from $0.75 to $0.51 per share following the ATM issuance.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38242,"accession_number":"0001437749-26-031005","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 8.01 disclosure centers on two dilutive capital-raising activities: (1) issuance of 888,400 shares through an ATM offering for $0.48 million in September 2026, and (2) issuance of Series I Warrants to purchase 37,130,001 shares in a public offering on August 3, 2026, with anti-dilution provisions that reduced the warrant exercise price from $0.75 to $0.51 per share following the ATM issuance. These equity issuances are material to shareholders as they substantially dilute existing ownership and signal ongoing capital needs for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:26:52.216184+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38241,"accession_number":"0001437749-26-031005","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the grant of Mexican Patent No. 436849 protecting Moleculin's proprietary lung-targeted liposomal Annamycin technology through 2040. This is a material intellectual property milestone that strengthens the company's global patent estate and supports long-term commercial protection of its lead clinical-stage asset. While not fitting a specific named event type, this is clearly an operational/strategic business event—a regulatory/IP milestone—that would affect a reasonable investor's assessment of the company's competitive position and asset value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:26:52.216184+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-09-23"},{"id":38242,"accession_number":"0001437749-26-031005","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 8.01 disclosure centers on two dilutive capital-raising activities: (1) issuance of 888,400 shares through an ATM offering for $0.48 million in September 2026, and (2) issuance of Series I Warrants to purchase 37,130,001 shares in a public offering on August 3, 2026, with anti-dilution provisions that reduced the warrant exercise price from $0.75 to $0.51 per share following the ATM issuance. These equity issuances are material to shareholders as they substantially dilute existing ownership and signal ongoing capital needs for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:26:52.216184+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-09-23"}]}